Free Trial

Maxim Group's Rating of Polaryx Therapeutics on 2/27/2026

On February 27, 2026, Maxim Group updated its outlook on Polaryx Therapeutics (NASDAQ:PLYX) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Maxim Group

DateCompanyAction
5/6/2026
Adeia Inc. stock logo
ADEA
Adeia
Set Price Target
5/6/2026
Diversified Healthcare Trust stock logo
DHC
Diversified Healthcare Trust
Set Price Target
5/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Downgrade
4/30/2026
Amazon.com, Inc. stock logo
AMZN
Amazon.com
Boost Price Target
4/28/2026
American Battery Technology Company stock logo
ABAT
American Battery Technology
Upgrade
4/28/2026
American Battery Technology Company stock logo
ABAT
American Battery Technology
Initiated Coverage
More Ratings From Maxim Group